Hemab Therapeutics closed a $157 million financing to advance a portfolio targeting ‘underserved’ coagulation disorders, including a pivotal program for Glanzmann thrombasthenia and an early clinical asset showing proof of mechanism. The round was led by Sofinnova Partners with participation from crossover and strategic investors. Hemab said proceeds will fund a pivotal trial of sutacimig next year and continued development of HMB‑002 and other programs. Management framed the raise as building the company into a specialized coagulation developer addressing rare bleeding conditions with high unmet medical need.